Reduces Triglycerides and Increases HDL-C

In the most recent National Cholesterol Education Program (NCEP) Guidelines, both high triglycerides and low HDL-C are independent risk factors for coronary heart disease.¹ Fenofibrates, such as LOFIBRA^®...

• Reduce triglycerides by 20% to 50%¹
• Increase HDL-C by 10% to 20%¹
• Reduce LDL-C by 5% to 20%^1*

* May be increased with high triglycerides

Hypertriglyceridemia Indication

LOFIBRA^® [fenofibrate tablets and capsules (micronized)] is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia usually obviates the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g., >2000 mg/dL) may increase the risk of developing pancreatitis. The effect of LOFIBRA^® in relation to this risk has not been adequately studied.

Hypercholesterolemia Indication

LOFIBRA^® [fenofibrate tablets and capsules (micronized)] is also indicated as adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacologic interventions alone has been inadequate.

LOFIBRA^® Tablets are also indicated to increase HDL-C in adult patients with hypercholesterolemia or mixed dyslipidemia.

©2010, Teva Pharmaceuticals USA 8750